P
Philippe Azam
Researcher at University of California, Davis
Publications - 4
Citations - 1019
Philippe Azam is an academic researcher from University of California, Davis. The author has contributed to research in topics: Cytotoxic T cell & IL-2 receptor. The author has an hindex of 4, co-authored 4 publications receiving 940 citations.
Papers
More filters
Journal ArticleDOI
Kv1.3 channels are a therapeutic target for T cell-mediated autoimmune diseases
Christine Beeton,Heike Wulff,Nathan Standifer,Philippe Azam,Katherine M. Mullen,Michael W. Pennington,Aaron Kolski-Andreaco,Eric Wei,Alexandra Grino,Debra Counts,Ping H. Wang,Christine J. LeeHealey,Brian S. Andrews,Ananthakrishnan Sankaranarayanan,Daniel Homerick,Werner W. Roeck,Jamshid Tehranzadeh,Kimber L. Stanhope,Pavel I. Zimin,Peter J. Havel,Stephen M Griffey,Hans Guenther Knaus,Gerald T. Nepom,George A. Gutman,Peter A. Calabresi,K. George Chandy +25 more
TL;DR: It is demonstrated that disease-associated autoreactive T cells from patients with type-1 diabetes mellitus or rheumatoid arthritis are mainly CD4+CCR7−CD45RA− effector memory T cells (TEM cells) with elevated Kv1.3 potassium channel expression, which ameliorate pristane-induced arthritis in rats and reduce the incidence of experimental autoimmune diabetes in diabetes-prone rats.
Journal ArticleDOI
Design of PAP-1, a Selective Small Molecule Kv1.3 Blocker, for the Suppression of Effector Memory T Cells in Autoimmune Diseases
Alexander Schmitz,Ananthakrishnan Sankaranarayanan,Philippe Azam,Kristina Schmidt-Lassen,Daniel Homerick,Wolfram Hänsel,Heike Wulff +6 more
TL;DR: A series of new phenoxyalkoxypsoralens that exhibit 2- to 50-fold selectivity for Kv1.3 as a target for immunosuppression and could potentially be developed into orally available immunomodulators are identified.
Journal ArticleDOI
The intermediate-conductance calcium-activated potassium channel KCa3.1 contributes to atherogenesis in mice and humans
Kazuyoshi Toyama,Heike Wulff,K. George Chandy,Philippe Azam,Girija Raman,Takashi Saito,Yoshimasa Fujiwara,David L. Mattson,Satarupa Das,James E. Melvin,Phillip F. Pratt,Ossama A. Hatoum,David D. Gutterman,David D. Gutterman,David R. Harder,Hiroto Miura +15 more
TL;DR: In vivo therapy with 2 KCa3.1 blockers, TRAM-34 and clotrimazole, significantly reduced the development of atherosclerosis in aortas of Apoe(-/-) mice by suppressing VSMC proliferation and migration into plaques, decreasing infiltration of plaques by macrophages and T lymphocytes, and reducing oxidative stress.
Journal ArticleDOI
Targeting Effector Memory T Cells with the Small Molecule Kv1.3 Blocker PAP-1 Suppresses Allergic Contact Dermatitis
Philippe Azam,Ananthakrishnan Sankaranarayanan,Daniel Homerick,Stephen M Griffey,Heike Wulff +4 more
TL;DR: It is proposed that PAP-1, a small molecule Kv1.3 blocker, could potentially be developed into a drug for the topical treatment of inflammatory skin diseases such as psoriasis.